Boothbay Fund Management’s NeuroSense Therapeutics NRSN Stock Holding History

Boothbay Fund Management’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,170	Closed	-$48K	–	2540
2022 Q1	$48K	Buy	+12,170	New	+$29K	﹤0.01%	2188

Other funds holding NRSN

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Boothbay Fund Management's NRSN Position: Q2 2022 in Review

Boothbay Fund Management sold out of NeuroSense Therapeutics (NRSN) in Q2 2022, closing a stake of 12,170 shares — an estimated $48K sold.

Boothbay Fund Management first reported a position in NRSN in Q1 2022 and held it in 1 quarter. The position peaked at $48K in Q1 2022. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2022.

Boothbay Fund Management reported no remaining NeuroSense Therapeutics position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 12,170 NeuroSense Therapeutics shares in Q2 2022, an estimated $48K.
Boothbay Fund Management first reported a position in NeuroSense Therapeutics in Q1 2022 and held it in 1 quarter.
Boothbay Fund Management's NeuroSense Therapeutics position peaked at $48K in Q1 2022.
7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.